All In Biotech

Drug Trial Radar · NCT00001082

The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3

Last checked: Nov 19, 2026Latest source record: Oct 1, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 505 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

505

Actual

Start

Dec 1996

Primary completion

Jan 1999

Study completion Aug 1999

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of adefovir dipivoxil in prolonging survival of patients with advanced HIV disease. In CMV prophylaxis substudy: To evaluate the efficacy of adefovir dipivoxil in preventing the development of CMV end-organ disease in patients with advanced HIV coinfected with CMV. The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection.

Conditions

  • Cytomegalovirus Infections
  • HIV Infections

Interventions

  • LevocarnitineDrug

    500 mg tablet taken orally daily

  • Adefovir dipivoxilDrug

    120 mg tablet taken orally daily

  • Adefovir dipivoxil placeboDrug

    Oral placebo tablet taken daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MorbidityTime frame: Throughout study

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Community Consortium / UCSF

    San Francisco, California

  • Denver CPCRA / Denver Public Hlth

    Denver, Colorado

  • Washington Reg AIDS Prog / Dept of Infect Dis

    Washington D.C., District of Columbia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • AIDS Research Alliance - Chicago

    Chicago, Illinois

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

    New Orleans, Louisiana

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr

    Detroit, Michigan

  • Henry Ford Hosp

    Detroit, Michigan

  • Southern New Jersey AIDS Cln Trials / Dept of Med

    Camden, New Jersey

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Partners in Research / New Mexico

    Albuquerque, New Mexico

  • Harlem AIDS Treatment Grp / Harlem Hosp Ctr

    New York, New York

  • The Research and Education Group

    Portland, Oregon

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Richmond AIDS Consortium / Div of Infect Diseases

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.